6 terminated. 6 Phase 2, 2 Phase 1, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 6 | Terminated 6 |
| Phase 1 | 2 | Terminated 2 |
| Phase 3 | 2 | Terminated 2 |
Follow Blindness: new trials by email Literature Review of Blindness trials Research Report on Blindness
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study to Evaluate the Efficacy Safety and Tolerability of QR-421a in Subjects With RP Due to Mutations in Exon 13 of the USH2A Gene With Early to Moderate Vision Loss (Celeste) QR-421a, Sham-procedure - Retinitis Pigmentosa, Usher Syndrome Type 2 | Phase 2 / Phase 3 | Terminated | Laboratoires Thea | 5 | 2021-12-15 | 2024-08-07 |
| Study to Evaluate the Efficacy Safety and Tolerability of Ultevursen in Subjects With RP Due to Mutations in Exon 13 of the USH2A Gene (Sirius) Ultevursen, Sham-procedure - Retinitis Pigmentosa, Usher Syndrome Type 2 | Phase 2 / Phase 3 | Terminated | Laboratoires Thea | 7 | 2021-12-08 | 2024-07-12 |
| An Open-Label Extension Study to Evaluate Safety & Tolerability of QR-421a in Subjects With Retinitis Pigmentosa RNA antisense oligonucleotide for intravitreal injection - Retinitis Pigmentosa, Usher Syndrome Type 2 | Phase 2 | Terminated | Laboratoires Thea | 21 | 2021-09-16 | 2024-08-07 |
| Extension Study to Study PQ-110-001 (NCT03140969) QR-110 - Leber Congenital Amaurosis 10, Blindness | Phase 1 / Phase 2 | Terminated | Laboratoires Thea | 9 | 2019-05-13 | 2024-10-15 |
| Fluoxetine for Visual Recovery After Ischemic Stroke Fluoxetine, Placebo - Acute Stroke, Visual Field Loss | Phase 2 | Terminated | Bogachan Sahin | 17 | 2016-05-01 | 2021-10-13 |
| Study of SAR421869 in Participants With Retinitis Pigmentosa Associated With Usher Syndrome Type 1B SAR421869 - Usher Syndrome, Retinitis Pigmentosa | Phase 1 / Phase 2 | Terminated | Sanofi | 9 | 2012-03-26 | 2022-04-28 |
Eye Diseases (4) · Retinal Diseases (4) · Retinitis Pigmentosa (4) · Usher Syndromes (4) · Vision Disorders (4) · Eye Abnormalities (3) · Eye Diseases, Hereditary (3) · Genetic Diseases, Inborn (1) · Hemianopsia (1) · Ischemic Stroke (1) · Leber Congenital Amaurosis (1) · Leber Congenital Amaurosis 10 (1) · Meckel Syndrome, Type 4 (1) · Neurologic Manifestations (1)
Nervous System Diseases (6) · Pathological Conditions, Signs and Symptoms (6) · Signs and Symptoms (6) · Congenital Abnormalities (5) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (5) · Neurologic Manifestations (5) · Sensation Disorders (5) · Abnormalities, Multiple (4) · Deaf-Blind Disorders (4) · Deafness (4) · Ear Diseases (4) · Genetic Diseases, Inborn (4) · Hearing Disorders (4) · Hearing Loss (4)
Intravitreal Injections (3) · Fluoxetine (1)
Laboratoires Thea (4) · Bogachan Sahin (1) · Sanofi (1)
United States (6) · France (2) · United Kingdom (2) · Belgium (1) · Canada (1) · Germany (1) · Netherlands (1)
Jose-Alain Sahel, MD, PhD (1) · Richard Weleber, MD (1)
PMID 24705452, PMID 33230035, PMID 36166771
2018 (1)